Company Overview
Nureca Limited provides home healthcare and wellness products in India. The company offers chronic disease products, such as nebulizers, blood pressure monitors, finger pulse oximeters, glucose meters, and thermometers, as well as connected products; orthopedic products, including massagers, pain management products, posture correctors, and rehabilitation products; and humidifiers and steamers, personal scales, yoga and exercise products, fitness tracking products, and dental and personal care products. It also provides mother and baby care products comprising baby feeding products, carry cots, baby skincare products, and bottle warmers and steamers; nutritional supplements and weight management products; and ECG products, fitness trackers, and smart weighing scales. In addition, the company provides orthopedic cushions, heating pads, and breast pumps. The company offers its products under the Dr Trust, Dr Physio, and Trumom brands. It markets its products through e-commerce platforms, distributors, retailers, and its websites. Nureca Limited was incorporated in 2016 and is based in Chandigarh, India.
Why Investors Should Care
Net profit has compounded at 41.7% per year over the last five years.
Recent Developments
- Mar 2026 Revenue of ₹146.96 Cr (+34.0% YoY); net profit ₹2.08 Cr.
- Trailing 12 Months Year-on-year growth — revenue +34.0%, earnings +146.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 9.7%, profit CAGR 41.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 9.70% |
| 1 Year: | 34.02% |
Compounded Profit Growth
| 5 Years: | 41.75% |
| 1 Year: | 146.10% |
Stock Price Performance
| 1 Year: | +37.52% |
| 6 Months: | +17.05% |
| 3 Months: | +39.21% |
| 1 Month: | -4.71% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.65 · Neutral
P/E of 152.94 is above the sector median of 41.64 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 41.7% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 152.9.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NURECA Nureca Limited NSEPHARMA | 322.70 | 152.94 | ₹307.92 Cr | 0.00% | 3.01% | 1.15% | 9.70% | 41.75% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,899.00 | 39.73 | ₹4.56 L Cr | 0.82% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,100.00 | 94.06 | ₹2.42 L Cr | 0.36% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,857.00 | 75.99 | ₹1.64 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.22% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA | 684.90 | 236.17 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,120.00 | 22.36 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 28.85 | ₹1.12 L Cr | 0.88% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 111.85 | ₹99,333.61 Cr | 0.13% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.23 Cr | 21.23 Cr | 31.35 Cr | 22.37 Cr | 16.97 Cr | 20.27 Cr | 31.19 Cr | - | 31.74 Cr | 34.18 Cr | 37.74 Cr | 39.64 Cr | 35.41 Cr | 40.34 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 18.97 Cr | 22.18 Cr | - | 25.25 Cr | 21.44 Cr | 24.69 Cr |
| Gross Profit | - | - | - | - | - | - | - | - | 12.77 Cr | 12.00 Cr | - | 14.40 Cr | 13.96 Cr | 15.65 Cr |
| Operating Expenses | 24.69 Cr | 24.13 Cr | 29.97 Cr | 26.62 Cr | 21.40 Cr | 22.63 Cr | 33.54 Cr | - | 12.09 Cr | 13.09 Cr | 34.47 Cr | 11.65 Cr | 11.86 Cr | 12.77 Cr |
| Operating Income | -4.02 Cr | -3.48 Cr | 79.00 L | -4.84 Cr | -5.03 Cr | -3.02 Cr | -2.97 Cr | - | 67.90 L | -1.09 Cr | 2.73 Cr | 2.75 Cr | 2.11 Cr | 2.88 Cr |
| EBITDA | -3.46 Cr | -2.90 Cr | 1.38 Cr | -4.25 Cr | -4.43 Cr | -2.36 Cr | -2.35 Cr | - | 3.19 Cr | 2.01 Cr | 3.27 Cr | 5.44 Cr | -4.76 Cr | 5.24 Cr |
| Interest Expense | 10.00 L | 12.00 L | 8.00 L | 11.00 L | 18.00 L | 15.00 L | 27.00 L | - | 62.00 L | 24.80 L | 46.00 L | 27.60 L | 30.00 L | 20.10 L |
| Pretax Income | -1.97 Cr | -93.00 L | 3.91 Cr | 95.00 L | -6.47 Cr | 2.62 Cr | -7.00 L | - | 2.05 Cr | 1.23 Cr | 4.59 Cr | 4.66 Cr | -5.51 Cr | 4.43 Cr |
| Tax Provision | 44.01 L | 22.00 L | 1.01 Cr | 78.00 L | 2.32 Cr | 96.00 L | -41.00 L | - | -41.60 L | 41.80 L | 96.99 L | 93.00 L | 58.10 L | 1.36 Cr |
| Net Income | -1.53 Cr | -71.00 L | 2.89 Cr | 17.00 L | -4.15 Cr | 1.66 Cr | -48.00 L | - | 2.47 Cr | 81.30 L | 3.63 Cr | 3.73 Cr | -6.09 Cr | 3.07 Cr |
| Diluted EPS | -1.53 | -0.71 | 2.89 | 0.17 | -4.15 | 1.66 | -0.48 | - | 2.47 | 0.81 | 3.63 | 3.91 | -6.45 | 3.21 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 62.00 Cr | 99.00 Cr | 213.00 Cr | - | 111.32 Cr | 91.93 Cr | 109.66 Cr | 146.96 Cr |
| Cost of Revenue | - | - | - | - | 75.53 Cr | 61.06 Cr | 68.70 Cr | 93.55 Cr |
| Gross Profit | - | - | - | - | 35.79 Cr | 30.87 Cr | 40.96 Cr | 53.42 Cr |
| Operating Expenses | 53.00 Cr | 90.00 Cr | 152.00 Cr | - | 52.93 Cr | 43.44 Cr | 50.79 Cr | 46.57 Cr |
| Operating Income | 9.00 Cr | 10.00 Cr | 62.00 Cr | - | -17.14 Cr | -12.57 Cr | -9.83 Cr | 6.85 Cr |
| EBITDA | 9.00 Cr | 10.00 Cr | 62.00 Cr | - | -8.02 Cr | 13.60 L | 4.07 Cr | 7.50 Cr |
| Interest Expense | 0 | 1.00 Cr | 2.00 Cr | - | 33.60 L | 31.80 L | 38.80 L | 51.00 L |
| Pretax Income | 9.00 Cr | 9.00 Cr | 62.00 Cr | - | -10.74 Cr | -2.54 Cr | 1.34 Cr | 4.98 Cr |
| Tax Provision | 2.70 Cr | 2.34 Cr | 16.12 Cr | - | -2.49 Cr | -75.00 L | 49.70 L | 2.90 Cr |
| Net Income | 6.00 Cr | 6.00 Cr | 46.00 Cr | - | -8.25 Cr | -1.79 Cr | 84.60 L | 2.08 Cr |
| Diluted EPS | 6,230.00 | 6,400.00 | 46.37 | 44.96 | -8.25 | -1.79 | 0.85 | 2.11 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | 24.00 Cr | 34.00 Cr | 186.00 Cr | - | 206.58 Cr | 205.16 Cr | 209.98 Cr | 196.16 Cr |
| Current Assets | - | - | - | - | 186.56 Cr | 192.59 Cr | 189.95 Cr | 114.68 Cr |
| Cash & Equivalents | - | - | - | - | 50.40 L | 14.06 Cr | 3.24 Cr | 1.46 Cr |
| Inventory | - | - | - | - | 34.48 Cr | 30.85 Cr | 39.92 Cr | 47.51 Cr |
| Receivables | - | - | - | - | 4.29 Cr | 1.61 Cr | 3.32 Cr | 7.75 Cr |
| Total Liabilities | - | - | - | - | 11.70 Cr | 12.05 Cr | 15.69 Cr | 15.40 Cr |
| Current Liabilities | - | - | - | - | 8.88 Cr | 9.27 Cr | 12.40 Cr | 13.78 Cr |
| Long Term Debt | - | - | - | - | 0 | 32.60 L | 1.05 Cr | 22.00 L |
| Total Debt | 0 | 10.00 Cr | 4.00 Cr | - | 3.33 Cr | 2.52 Cr | 4.97 Cr | 2.26 Cr |
| Total Equity | 8.01 Cr | 15.01 Cr | 163.00 Cr | - | 194.88 Cr | 193.11 Cr | 194.28 Cr | 180.76 Cr |
| Shares Outstanding | - | - | - | - | 1.00 Cr | 1.00 Cr | 1.00 Cr | 95.42 L |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 0 | -8.00 Cr | 35.00 Cr | - | 10.23 Cr | -2.71 Cr | -19.08 Cr | 3.30 Cr |
| Investing Cash Flow | -0 | -0 | -110.00 Cr | - | -16.46 Cr | 17.58 Cr | 8.44 Cr | 14.49 Cr |
| Financing Cash Flow | -0 | 8.00 Cr | 92.00 Cr | - | -1.51 Cr | -1.30 Cr | -16.90 L | -19.56 Cr |
| Capital Expenditure | 0 | 0 | -1.00 Cr | - | -39.60 L | -1.09 Cr | -4.32 Cr | -6.83 Cr |
| Free Cash Flow | 0 | -8.00 Cr | 34.00 Cr | - | 9.83 Cr | -3.80 Cr | -23.41 Cr | -3.53 Cr |
| Net Change in Cash | 0 | -0 | 17.00 Cr | - | -7.74 Cr | 13.56 Cr | -10.81 Cr | -1.77 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 32.2% | 33.6% | 37.4% | 36.3% |
| Operating Margin % | 14.5% | 10.1% | 29.1% | - | -15.4% | -13.7% | -9.0% | 4.7% |
| Net Margin % | 9.7% | 6.1% | 21.6% | - | -7.4% | -2.0% | 0.8% | 1.4% |
| ROE % | 74.9% | 40.0% | 28.2% | - | -4.2% | -0.9% | 0.4% | 1.2% |
| ROCE % | - | - | - | - | -8.7% | -6.4% | -5.0% | 3.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NURECA
Nureca returns to profit in Q1FY27 with revenue growth - scanx.trade
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOOW9udGphdmZNWkFjekZZUUZ2bHhHUGJ2eWRzbzBERTZKeFdqZE1LUXdDVHgtMGZ4SkI0a0JMMVBlUDBOd3hzNkxWeTVtLXYwTVZ0elJjMEl3RzVMbER2S0FYZXZjXzg2VjBCVUVaYnhCUDhQT0dCX3FWQ0ZBdmVocUswRzdmQlpQZjRHaW…
With EPS Growth And More, Nureca (NSE:NURECA) Makes An Interesting Case - simplywall.st
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNNHdfVmtNSklfM2xYOFJQelZDakRIbF9ZNFZHV0RTcVFYWVl2ZEtxRlhZN2dRQm5IeGpTbXNsRy1tT3pVemQxNUNIckQ0Mkp2UzA0N29EcjdoRTd5ak5BanByVUlvQ0RMMmtMM2x4eW40SWIydHc4T0k0U3RwMVhqd0lRRFVhTE1ienNFcT…
Nureca Ltd. Peer Comparison – Compare with Others - Value Research
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxQdUlxVE1sLTIxWnJUUk1UTER1LU11Nkx2dlE2QzhRUVZibnNHRmgtOFktemNtdmZ5NFdtLTk2TUVUR2VQQW80clM0SHlreDlvcEc3R3VLMHB5NkZHVEI0bjYxa1ZubkpqcGlHaFhDRmxxWHMxX3k1RHFlUDJmcXpDOTc0MA?oc=5" targe…
NURECA Q2 2026 Earnings: Revenue Surges 34% to ₹146.96 Cr; EPS Arrives at ₹2.11 - Earnings Revision Upgrade - siam.in
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQbEhadFIxUDVsX2lyWHhrNVQtRmpfQUxQbHprY2V5TkFPTjByZ2VNWGN4cVVZQ0ZpeW1oRGNIX0NYMkJJUmtNMHZEN003U0tpN0xxOFpLcVpyeHk0ZGVSZFRSUlU4TWgzZUNya2hETzFuN1F1RVI5UmU2ZndocDhpUXp1bW5iS3p1YU5yaG…
Nureca Stock Prediction 2026: Analyst Targets, Forecast and Key Levels - Univest
<a href="https://news.google.com/rss/articles/CBMiY0FVX3lxTE1hVWwxZzQ5WkkyWlZBaUlWLTVhQ1dZaFhaVmZRZ0hEYWgtUDFBZmhkYjNPS3h4WVBXbU1leVJrcUU1WmpnVGFoRDNTdE41M3FGX2dmWEp5STF1OHh3QUJnVjJvVQ?oc=5" target="_blank">Nureca Stock Prediction 2026: Ana…
Nureca Limited (NURECA.NS) Faces Mild Selling Pressure, Holds Above Key Support - Percent Below MA - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQcG5Vcm5JdzlmU0dPV0ZCYzN2RURPckU5UUdVSkl1VWlOd3hyV1pmXy1saFN1X0pCXzBZcGFVUHYxSmY4VlR1VFppV0VUWHZNUWZkeURpaHA4U0pNS08xc1dUNElRT2l0WGI5d2ZXQ0U3LS1weXJKdi1uS0tLZHF6ellON0o4bnFiZlVlMG…
NURECA — Frequently Asked Questions
What is the current share price of Nureca Limited (NURECA)?
As of 2026-09-08 04:53 IST, Nureca Limited (NURECA) trades at ₹322.70 on NSE. Its 52-week range is ₹206.75 to ₹346.30.
What is the market capitalisation of NURECA?
Nureca Limited (NURECA) has a market capitalisation of ₹307.92 Cr on NSE.
What is the P/E ratio of NURECA?
NURECA trades at a trailing price-to-earnings (P/E) ratio of 152.94. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 1.81.
What is the return on equity (ROE) of NURECA?
NURECA has a return on equity (ROE) of 1.15%. Its return on capital employed (ROCE) is 3.01%.
Is NURECA a good stock to buy?
This page provides a data-driven analysis of Nureca Limited (NURECA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.